HeartSciences Inc. (NASDAQ:HSCS) Short Interest Down 37.2% in July

HeartSciences Inc. (NASDAQ:HSCS) saw a significant decrease in short interest in July. As of July 15th, there was short interest totaling 77,601 shares, a decrease of 37.2% from the June 30th total of 123,640 shares. Based on an average daily volume of 58,703 shares, the short-interest ratio is currently 1.3 days. Approximately 2.6% of the shares of the stock are short sold.

Key Stories Impacting HeartSciences

Here are the key news stories impacting HeartSciences this week:

• Positive Sentiment: Maxim Group raised its FY2028 EPS forecast to a loss of $2.13 per share from a loss of $2.21, indicating an improved outlook for the company’s longer-term earnings trajectory.
• Positive Sentiment: The firm also improved estimates for Q1, Q2, Q3 and Q4 2028, with the largest revision coming in Q4 2028, now forecast at a loss of $0.34 per share versus $0.35 previously. These upgrades may be supporting investor sentiment.
• Neutral Sentiment: Despite the improvements, Maxim still projects substantial losses, including a $2.98-per-share loss for FY2027 and a $2.13-per-share loss for FY2028. The company’s current-year consensus estimate remains a loss of $3.02 per share.
• Negative Sentiment: Maxim lowered its forecasts for Q1, Q2 and Q3 2027 and reduced its FY2027 estimate to a loss of $2.98 per share from $2.93. These downward revisions highlight ongoing near-term operating and funding risks.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently bought a new stake in HeartSciences stock. Geode Capital Management LLC bought a new stake in shares of HeartSciences Inc. (NASDAQ:HSCS) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.51% of HeartSciences as of its most recent filing with the SEC. 17.24% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, HeartSciences presently has a consensus rating of “Hold” and a consensus target price of $8.00.

HeartSciences Trading Up 4.8%

Shares of NASDAQ:HSCS opened at $2.18 on Friday. HeartSciences has a 1-year low of $1.63 and a 1-year high of $3.93. The stock has a market capitalization of $8.50 million, a P/E ratio of -0.55 and a beta of 1.78. The business has a 50-day moving average price of $2.30 and a two-hundred day moving average price of $2.47.

HeartSciences (NASDAQ:HSCS) last issued its earnings results on Thursday, July 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.22). As a group, equities analysts predict that HeartSciences will post -3.04 EPS for the current year.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.